Here are the Phase II Campath results.
http://www.genzyme.com/corp/investors/G ... 050207.asp
I think they are impressive for those with RR MS (I'm biased because I've seen excellent results following my first infusion last November). And the impressive reduction in relapses is when compared with Rebif.
These sorts of treatments are riskier than the CRAB drugs, but the risks identified to date can be monitored and treated. And you don't see ...